Fresh from haul­ing in GSK’s bud­get-priced gene ther­a­py group, Or­chard har­vests $150M mega-round. Is it time to IPO?

Just a few months ago Or­chard Ther­a­peu­tics was hand­ed the op­por­tu­ni­ty of tak­ing over Glax­o­SmithK­line’s gene ther­a­py group, which had pushed the field’s sec­ond prod­uct, Strimvelis, to the Eu­ro­pean mar­ket — with­out see­ing much in the way of a re­turn.

This morn­ing, Or­chard is back in the news, adding $150 mil­lion to the re­port­ed $140 mil­lion it had al­ready raised to get to this stage. And that may well in­clude an IPO in the near fu­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER